Clinical trials
Progression clinical trials
Below are recruiting progression clinical trials, each written for real people, not researchers. We’re tracking 711 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06276634Recruiting
Low-Oxygen Therapy for People With Multiple Sclerosis
This study tests whether brief, controlled low-oxygen episodes (called intermittent hypoxia) can improve motor function in people with MS. It may help strengthen walking and daily movement.
Chicago, IllinoisAges 18–75 - NCT06254326RecruitingPhase 1
Immune cell therapy for recurrent oligodendroglioma
This trial tests a personalized immune cell therapy for adults with a specific type of brain tumor (oligodendroglioma) that has come back. The treatment uses your own immune cells to target the tumor.
Gainesville, FloridaAges 18–89 - NCT06264180RecruitingPhase 3
Viral therapy and nivolumab for advanced melanoma
This trial tests a combination of an investigational viral therapy (VO) and the immunotherapy nivolumab for people with advanced melanoma that has stopped responding to previous anti-PD-1 and anti-CTLA-4 treatments. The goal is to see if this combination works better than other standard treatments your doctor might choose.
Gilbert, ArizonaAges 12 years+ - NCT03650673Recruiting
Study of early finger osteoarthritis symptoms over time
This study follows people with early finger (hand) osteoarthritis symptoms to better understand how the condition starts and changes. You may be asked for blood tests, symptom checks, and imaging to see what’s happening in the joints.
MontpellierAges 18–60 - NCT06224283Recruiting
Predicting desmoid tumor growth after cryoablation
This study looks at whether a special MRI analysis (radiomics) can better predict if a desmoid tumor will grow back after freezing treatment (cryoablation) compared to standard methods. It may help doctors decide on future treatment steps.
BolognaAges Any age - NCT06221592Enrolling by invitation
New glasses for slowing myopia in children
This study is testing the safety and comfort of new glasses with special lenses designed to slow down nearsightedness in children. It compares differences between the new lenses and regular lenses, and the child will wear them for a period of time to see how they feel and if there are any concerns.
Shanghai, Shanghai MunicipalityAges 6–14 - NCT05783804Recruiting
Early cholesterol-lowering to help reverse artery plaque
This trial studies whether starting strong cholesterol-lowering treatment early can reduce or reverse plaque in the arteries. It may help protect the heart over time, especially for people with inherited high cholesterol.
Amsterdam, North HollandAges 18–50 - NCT06193928Recruiting
Long-term safety study of Livmarli in ALGS or PFIC
This study is following patients who are already taking Livmarli (maralixibat) for Alagille syndrome or PFIC to see how safe and effective it is over the long term.
Los Angeles, CaliforniaAges Any age - NCT06206369Recruiting
Ai tool for predicting vascular disease risk
This study is collecting medical information from people with abdominal aortic aneurysms or peripheral artery disease to build an AI tool that can better predict how these conditions progress. The goal is to help doctors give more personalized care.
HelsinkiAges 40–90 - NCT06191198RecruitingPhase 2
Communication Bridge 3: Speech therapy for PPA
This study tests a web-based speech therapy program called Communication Bridge for people with Primary Progressive Aphasia (PPA) and their communication partners. The goal is to improve communication skills and quality of life.
Chicago, IllinoisAges 18–100 - NCT06199479RecruitingPhase 1
Using imaging to tell real tumor growth from treatment effects
This trial uses special imaging to tell the difference between real brain tumor growth and a treatment reaction that looks like a tumor. It may help you and your doctor decide if a biopsy is needed.
Houston, TexasAges 18 years+ - NCT06162884Recruiting
Using one scan to predict early scarred lung disease
This study uses a single lung scan to find early signs of progressive scarring (fibrosis) in people with pulmonary fibrosis. It may help doctors predict which patients will get worse faster.
Los Angeles, CaliforniaAges 18 years+ - NCT06167785RecruitingPhase 2
Study of zanubrutinib and tislelizumab for lymphoma after CAR-T
This trial tests two new drugs (zanubrutinib and tislelizumab) for people with large B-cell lymphoma that has come back or not responded after CAR-T therapy. The goal is to see if these drugs can help when CAR-T hasn't worked.
Toronto, OntarioAges 18 years+ - NCT06180356RecruitingPhase 2
Niraparib after surgery for ovarian cancer with limited spread
This trial is testing a second course of niraparib (a PARP inhibitor) after surgery for ovarian cancer that has come back in just a few spots. It aims to see if restarting niraparib can help keep the cancer from coming back again.
A CoruñaAges 18 years+ - NCT06155032Recruiting
Clot Removal for Worsening Mild Stroke
This trial tests whether emergency clot removal (endovascular therapy) can help people whose mild stroke gets worse within a week. It's for those who have a blockage in a large brain artery and enough healthy brain tissue to save.
Fuyang, AnhuiAges 18 years+ - NCT06112990RecruitingPhase 3
Creatine and exercise to keep muscles strong in prostate cancer
This trial tests if taking creatine plus doing resistance exercises at home can help men with prostate cancer maintain muscle mass and slow cancer growth. You would take creatine or a placebo for 52 weeks and do simple strength exercises twice a week.
Salt Lake City, UtahAges 18 years+ - NCT06106802RecruitingPhase 2
Testing lazertinib and tepotinib for EGFR lung cancer that progressed on lazertinib
This trial tests a combination of two targeted drugs, lazertinib and tepotinib, for people with advanced EGFR-mutant non-small cell lung cancer whose tumors show MET overactivity (high MET levels or MET gene copies) and have grown despite prior treatment with lazertinib. It aims to see if adding tepotinib can overcome that resistance.
Seoul, Gangnam-guAges 19 years+ - NCT06103669Recruiting
Local treatment for limited cancer spread
This trial tests whether using local treatments (like targeted radiation or ablation) on a few new spots of cancer can help people whose cancer is otherwise stable on their current treatment. It enrolls people with various solid tumors, such as breast, gynecologic, head & neck, sarcoma, or other types.
Sacramento, CaliforniaAges 18 years+ - NCT06081400Recruiting
Freezing vs. medication for growing desmoid tumors
This trial compares freezing the tumor (cryoablation) with standard medication for people with desmoid tumors that have grown or caused more symptoms. It aims to see which approach works better when the tumor is not in the belly.
BesançonAges 13 years+ - NCT06093906Recruiting
Positive processes and transition to health (PATH) study
This study tests a new therapy that may help people recover after a stressful life event. Over about 6 weeks, you'll work with a coach to retrain your brain's patterns and feel more in control again, as well as reconnect with positive activities.
Newark, DelawareAges 18–65 - NCT06101277Recruiting
Local therapy for limited new cancer growth in digestive cancers
This trial tests a cancer treatment that uses local therapies (like radiation or targeted heat) to destroy a small number of growing spots. It is for people with certain gastrointestinal cancers whose main treatment is working well except for a few new spots, so they can avoid switching to a different drug right away.
Sacramento, CaliforniaAges 18 years+ - NCT06101290Recruiting
Local therapy for progressing spots in genitourinary cancers
This trial explores whether treating only the new or growing spots of cancer (called oligoprogression) with local therapies like radiation or ablation can help you stay on your current systemic treatment longer. It is for people with prostate, bladder, or kidney cancer that has started to progress in a few places.
Sacramento, CaliforniaAges 18 years+ - NCT06065371RecruitingPhase 1
Sacituzumab govitecan plus capecitabine for advanced GI cancers
This trial tests a combination of two drugs—sacituzumab govitecan (targeted therapy) and capecitabine (chemotherapy)—for people with advanced stomach, colon, or pancreatic cancer that has stopped responding to standard treatments.
Detroit, MichiganAges 18 years+ - NCT06079567Recruiting
Study of FSHD2 progression over 18 months
This study follows people with FSHD2 over 18 months to learn how the disease progresses and affects daily life. No new drugs are tested—just regular check-ups and an MRI scan.
LeuvenAges 18–75
Hear when a new Progression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for progression?
- Yes. Clin2 currently lists 711 recruiting progression studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a progression trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a progression trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.